Cosentyx from Novartis AG - expanded hidradenitis coverage in Europe

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 16:03. Details in the imprint.

Cosentyx from Novartis AG sits in a refrigerated box, a slim pre-filled pen waiting in the hand of a dermatologist who has finally something targeted for hidradenitis suppurativa. The click is quiet, the injection is smooth, and the promise is clear.

What Cosentyx is targeting

Cosentyx is a human monoclonal antibody that blocks interleukin-17A, a key cytokine in inflammatory pathways underlying several immune-mediated diseases.Novartis official Cosentyx page It is already established for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in many markets.

In Europe, Cosentyx recently gained an extended indication for moderate to severe hidradenitis suppurativa in adults, following a positive opinion and approval by the European Medicines Agency based on phase III trial data.EMA product information on Cosentyx This builds out Novartis's dermatology franchise with another chronic inflammatory condition.

How the therapy is given

Cosentyx is administered by subcutaneous injection either via pre-filled syringe or autoinjector pen, with dosing regimens depending on the specific indication.US prescribing information for Cosentyx For hidradenitis suppurativa, an initial loading phase is followed by maintenance dosing at regular intervals.

Doctors like Dr. Martina Keller, a Zurich-based dermatologist quoted in Swiss specialist media, describe the tactile feel of the Cosentyx pen as "tidy and controlled", which matters when patients self-inject at home after training. The injection time is short, which reduces anxiety for many users.

Where Cosentyx fits in practice

For hidradenitis suppurativa, Cosentyx enters a treatment landscape previously dominated by adalimumab, offering an IL-17A-based alternative for patients who fail or cannot tolerate anti-TNF therapy.Novartis press release on EU hidradenitis approval Trial data showed meaningful reductions in abscesses and nodules for many participants.

Patients report that in everyday life the biggest difference is fewer painful flare-ups and less drainage, making simple routines such as sitting in a car seat or wearing a backpack more feasible. That practical gain rather than pure lab numbers is what dermatologists like Keller emphasise to hesitant patients.

Pricing and availability picture

Cosentyx is a premium biologic with list prices running into several hundred euros per monthly treatment in many EU markets, subject to national reimbursement schemes and confidential discounts. In Switzerland and Germany, coverage typically depends on specialist prescription and prior authorisation by health insurers.

The drug is available across most of the European Union via hospital pharmacies and specialty distributors, with home-injection supported through nurse training programs. Outside Europe, Cosentyx is marketed in the US, Japan and other regions with local labelling differences, but the same core IL-17A mechanism.

What this means for Novartis

For Novartis, Cosentyx forms a central pillar of its immunology and dermatology portfolio, alongside other biologics in development. Management, led by CEO Vasant Narasimhan, has repeatedly highlighted Cosentyx as a driver of mid-single-digit sales growth in the core Innovative Medicines division.

All told, Cosentyx's extended hidradenitis indication adds depth rather than flash to Novartis's biologics story, reinforcing recurring revenues in Europe over the coming years. Novartis shares (ISIN CH0012005267) trade on SIX Swiss Exchange, giving investors exposure to this and other specialty medicines.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.